GSK's RSV Vaccine Arexvy Wins FDA Nod for High-Risk Younger AdultsZacks Investment Research • 03/16/26
GSK's RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased RiskBusiness Wire • 03/13/26
GSK plc (GSK) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking Alpha • 03/11/26
FDA Approves Leucovorin—But Not For Autism, Even After Trump Admin Officials Touted Drug Last YearForbes • 03/10/26
US FDA approves leucovorin for ultra- rare genetic disorder causing autism-like symptomsReuters • 03/10/26
FDA approves leucovorin as first drug for rare genetic disorder, after touting it as autism treatmentCNBC • 03/10/26
GSK pays $950m for a pulmonary hypertension drug designed to avoid the bleeding risk that limits rival treatmentsProactive Investors • 02/25/26
35Pharma to be Acquired by GSK to Accelerate Development of HS235, a Potential Best-in-Class Investigational Medicine for Pulmonary Hypertension (PH)GlobeNewsWire • 02/25/26
Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing ContractBusiness Wire • 02/23/26
GSK's AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study ShowsBusiness Wire • 02/18/26